TOP TIERMARKET NEWSWIRE

News & sentiment

ABCELLERA BIOLOGICS (ABCL) — News & AI sentiment

ABCELLERA BIOLOGICS (ABCL) news roundup. 9 stories aggregated over the last 30 days. Average 30-day sentiment is 61.3/100. Recent insider activity (SEC Form 4, 90-day window): 4 purchases totalling $1.5M and 0 sales totalling $0 — net buying of $1.5M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

0

30d stories

9

avg sentiment 61.3/100

Insider net (90d)

$1.5M

4 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

ABCL news in the last 24 hours, 7 days, 30 days and 90 days

How much ABCL coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	ABCL stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	0	—	no coverage
Last 30 days	9	61.3/100	ABCL headlines →
Last 90 days	76	59.2/100	ABCL headlines →

Latest stories on ABCL

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

StockTitan56 · neutralgeneral

Sep 2

HHS said to be eyeing two new FDA deputy commissioners for technology and drugs

Seeking Alpha58 · neutralgeneral

Aug 25

AbCellera rises 17.0%

The Fly67 · bullishearnings

Aug 25

AbCellera rises 10.7%

The Fly63 · neutralgeneral

Aug 25

AbCellera Biologics call volume above normal and directionally bullish

The Fly62 · neutralgeneral

Aug 19

AI Drug Discovery Advances: AbCellera’s Integrated Platform Draws Investor Focus as Industry Shifts to Function-Based Models August 19, 2026

MarketChameleon67 · bullishproduct/pr

Aug 19

AbCellera 17.4M share Secondary priced at $9.75

The Fly34 · bearishgeneral

Aug 17

AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity

Yahoo Finance78 · bullishproduct/pr

Aug 16

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

Yahoo Finance67 · bullishproduct/pr

Aug 14

AbCellera Biologics Inc. (ABCL) files 8-K

SEC 8-K50 · neutralgeneral

Aug 13

AbCellera Biologics prices oversubscribed $200M offering at $9.75/share

Seeking Alpha24 · bearishgeneral

Aug 13

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

StockTitan24 · bearishgeneral

Aug 13

AbCellera (ABCL) Q2 2026 Earnings Call Transcript

Yahoo Finance56 · neutralearnings

Aug 13

AbCellera (ABCL) Q2 2026 Earnings Call Transcript

The Motley Fool56 · neutralearnings

Aug 13

AbCellera Biologics stock analysis: momentum vs. fundamentals

Investing.com Markets55 · neutralgeneral

Aug 12

AbCellera’s Strong Phase 2 Data Spotlight New Highs and Next Steps for ABCL635 August 12, 2026

MarketChameleon73 · bullishproduct/pr

Aug 12

Why is Abcellera Biologics stock sliding today?

Investing.com Markets34 · bearishgeneral

Aug 11

AbCellera stock falls on $200M public offering launch

Investing.com Markets24 · bearishgeneral

Aug 11

AbCellera: Excellent Phase 2 Data In Menopause But The Platform Narrative Is Fading

Seeking Alpha58 · neutralproduct/pr

Aug 11

These Have the Market Hot Zone Catalysts and Setups

GlobeNewswire57 · neutralgeneral

Aug 11

These Have the Market Hot Zone Catalysts and Setups

Business Insider57 · neutralgeneral

Aug 11

AbCellera announces $200M common stock, warrants offering

The Fly24 · bearishgeneral

Aug 11

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

StockTitan28 · bearishgeneral

Aug 11

ABCL Phase 2 Results Spark Renewed Interest: 83% Reduction in Vasomotor Symptoms Stands Out August 11, 2026

MarketChameleon73 · bullishproduct/pr

Aug 11

Truist raises AbCellera stock price target on trial results

Investing.com Analyst Ratings63 · neutralanalyst

Aug 11

Open ABCL in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →